CanSino Biologics Inc.
CASBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.26 | -0.06 | 0.11 | -0.03 |
| FCF Yield | -8.69% | -29.56% | -20.80% | 2.24% |
| EV / EBITDA | -69.77 | -3.54 | -10.28 | 17.34 |
| Quality | ||||
| ROIC | -5.73% | -24.72% | -10.99% | 18.90% |
| Gross Margin | 70.37% | -253.78% | -18.10% | 69.85% |
| Cash Conversion Ratio | 0.44 | 0.46 | 1.59 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.17% | -56.86% | 246.01% | 1,134.86% |
| Free Cash Flow Growth | 58.97% | 48.47% | -465.11% | 209.63% |
| Safety | ||||
| Net Debt / EBITDA | -4.16 | -0.40 | 0.53 | -2.21 |
| Interest Coverage | -6.73 | -31.73 | -33.11 | 95.05 |
| Efficiency | ||||
| Inventory Turnover | 0.87 | 3.46 | 1.80 | 1.48 |
| Cash Conversion Cycle | 676.63 | 747.83 | 511.18 | 22.71 |